Uncertainties of testing methods: What do we (want to) know about carcinogenicity?

An approach to systematically describe the uncertainties and complexity of the standard animal testing and assessment approach for carcinogenicity is explored by using a OECD Guidance Document that was originally developed for reporting defined in vitro approaches to testing and assessment. The format is suitable for this re-purposing and it appears that the potential multitude of approaches for integrating and interpreting data from standard animal testing may ultimately be conceptually similar to the challenge of integrating relevant in vitro and in silico data. This structured approach shall allow 1) fostering interest in developing improved defined in silico and in vitro approaches; 2) the definition of what type of effects should be predicted by the new approach; 3) selection of the most suitable reference data and assessments; 4) definition of the weight that the standard animal reference data should have compared to human reference data and mechanistic information in the context of assessing the fitness of the new in vitro and in silico approach; 5) definition of a benchmark for the minimum performance of the new approach, based on a conceptual recognition that correlation of alternative assessment results with reference animal results is limited by the uncertainties and complexity of the latter. A longer term perspective is indicated for evolving the definition of adversity for classification and regulatory purposes. This work will be further discussed and developed within the OECD expert group on non-genotoxic carcinogenicity IATA development.

[1]  I. Berenblum,et al.  The Mechanism of Carcinogenesis. A Study of the Significance of Cocarcinogenic Action and Related Phenomena , 1941 .

[2]  H DRUCKREY,et al.  [Mechanism of carcinogenesis]. , 1954, Acta - Unio Internationalis Contra Cancrum.

[3]  P R Taylor,et al.  Prevalence of disease-related DNA polymorphisms among participants in a large cancer prevention trial. , 1999, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[4]  Bas J Blaauboer,et al.  Quantitative in vitro to in vivo extrapolation (QIVIVE): An essential element for in vitro-based risk assessment. , 2015, Toxicology.

[5]  Thomas Hartung,et al.  Green toxicology. , 2014, ALTEX.

[6]  Martin Paparella,et al.  International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes , 2015, Archives of Toxicology.

[7]  A. B. Hill The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.

[8]  K Yamagiwa,et al.  Experimental study of the pathogenesis of carcinoma , 1977, CA: a cancer journal for clinicians.

[9]  M. V. Asselt,et al.  Coping with Complexity, Uncertainty and Ambiguity in Risk Governance: A Synthesis , 2011, AMBIO.

[10]  C Rudén,et al.  The use and evaluation of primary data in 29 trichloroethylene carcinogen risk assessments. , 2001, Regulatory toxicology and pharmacology : RTP.

[11]  Thomas Hartung,et al.  "ToxRTool", a new tool to assess the reliability of toxicological data. , 2009, Toxicology letters.

[12]  N. Downes,et al.  Regulatory Forum Opinion Piece: Carcinogen Risk Assessment , 2015, Toxicologic pathology.

[13]  J. W. Cook,et al.  106. The isolation of a cancer-producing hydrocarbon from coal tar. Parts I, II, and III , 1933 .

[14]  Kevin McNally,et al.  PopGen: A virtual human population generator. , 2014, Toxicology.

[15]  Kevin McNally,et al.  A probabilistic model of human variability in physiology for future application to dose reconstruction and QIVIVE , 2015, Front. Pharmacol..

[16]  Martin Paparella,et al.  Uncertainty of testing methods--what do we (want to) know? , 2013, ALTEX.

[17]  Cheryl A Murphy,et al.  Development and application of the adverse outcome pathway framework for understanding and predicting chronic toxicity: II. A focus on growth impairment in fish. , 2015, Chemosphere.

[18]  J. P. Van Oosterhout,et al.  The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. , 1997, Regulatory toxicology and pharmacology : RTP.

[19]  C Helma,et al.  Data quality in predictive toxicology: reproducibility of rodent carcinogenicity experiments. , 2001, Environmental health perspectives.

[20]  Alexandra Maertens,et al.  Integrated testing strategies for safety assessments. , 2013, ALTEX.

[21]  Pallav Sengupta,et al.  Men and mice: Relating their ages. , 2016, Life sciences.

[22]  R. Peto,et al.  The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010 , 2011, British Journal of Cancer.

[23]  Chemicals Regulation Directorate Investigation of the state of the art on identification of appropriate reference points for the derivation of health-based guidance values (ADI, AOEL and AAOEL) for pesticides and on the derivation of uncertainty factors to be used in human risk assessment , 2013 .

[24]  Wei-Ho Chung,et al.  Probabilistic Model , 2009, Encyclopedia of Database Systems.

[25]  A. B. Hill,et al.  "The Environment and Disease: Association or Causation?" (1965), by Austin Bradford Hill , 2017 .

[26]  Lester B Lave,et al.  Implications of the lack of accuracy of the lifetime rodent bioassay for predicting human carcinogenicity. , 2003, Regulatory toxicology and pharmacology : RTP.

[27]  Critical reading of epidemiological papers , 2005 .

[28]  Carolyn Vickers,et al.  IPCS framework for analysing the relevance of a cancer mode of action for humans , 2006 .

[29]  Mardas Daneshian,et al.  Consensus report on the future of animal-free systemic toxicity testing. , 2014, ALTEX.

[30]  Mark D Thornquist,et al.  DNA repair genotype and lung cancer risk in the beta-carotene and retinol efficacy trial. , 2013, International journal of molecular epidemiology and genetics.

[31]  Richard W. Lewis,et al.  The mouse carcinogenicity study is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides , 2010, Critical reviews in toxicology.

[32]  Daniel L Villeneuve,et al.  Environmental surveillance and monitoring—The next frontiers for high‐throughput toxicology , 2016, Environmental toxicology and chemistry.

[33]  Jonathan Borak,et al.  Hormesis: Implications for Cancer Risk Assessment , 2005, Dose-response : a publication of International Hormesis Society.

[34]  Weihsueh A. Chiu,et al.  Addressing Human Variability in Next-Generation Human Health Risk Assessments of Environmental Chemicals , 2012, Environmental health perspectives.

[35]  Munn Sharon,et al.  Thresholds for Endocrine Disrupters and Related Uncertainties , 2013 .

[36]  I. Shlyakhter,et al.  An empirical examination of factors influencing prediction of carcinogenic hazard across species. , 1995, Regulatory toxicology and pharmacology : RTP.

[37]  T. Hartung Look back in anger - what clinical studies tell us about preclinical work. , 2013, ALTEX.

[38]  Emanuela Testai Dose-response relationship: Monotone vs non-monotone curve , 2015 .

[39]  Martin Paparella,et al.  International regulatory needs for development of an IATA for non-genotoxic carcinogenic chemical substances. , 2016, ALTEX.

[40]  Lloyd Demetrius,et al.  Aging in Mouse and Human Systems , 2006, Annals of the New York Academy of Sciences.

[41]  Anne M. Baldeshwiler History of FDA good laboratory practices , 2003 .

[42]  Sebastian Hoffmann,et al.  Guidance on assessing the methodological and reporting quality of toxicologically relevant studies: A scoping review. , 2016, Environment international.

[43]  David W Gaylor,et al.  Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens? , 2005, Regulatory toxicology and pharmacology : RTP.

[44]  Petra S Kern,et al.  Integrating non-animal test information into an adaptive testing strategy - skin sensitization proof of concept case. , 2011, ALTEX.

[45]  Laura N. Vandenberg,et al.  Should oral gavage be abandoned in toxicity testing of endocrine disruptors? , 2014, Environmental Health.

[46]  Andrew Williams,et al.  Integrating toxicogenomics into human health risk assessment: Lessons learned from the benzo[a]pyrene case study , 2015, Critical reviews in toxicology.

[47]  Igor Linkov,et al.  For nanotechnology decisions, use decision analysis , 2013 .

[48]  Katsusaburo Yamagiwa,et al.  Experimental Study of the Pathogenesis of Carcinoma , 1918 .

[49]  Valérie Zuang,et al.  A Modular Approach to the ECVAM Principles on Test Validity , 2004, Alternatives to laboratory animals : ATLA.

[50]  M Blettner,et al.  Critical reading of epidemiological papers. A guide. , 2001, European journal of public health.

[51]  Guidance on information requirements and chemical safety assessment , 2008 .

[52]  Raymond R Tice,et al.  Genetic toxicology in the 21st century: Reflections and future directions , 2011, Environmental and molecular mutagenesis.

[53]  Lars Carlsen,et al.  On the ranking of chemicals based on their PBT characteristics: comparison of different ranking methodologies using selected POPs as an illustrative example. , 2013, Chemosphere.

[54]  N. Andersson Regulatory Perspective on Non-Monotonic Dose-Response Curves and “Low dose effects” , 2015 .

[55]  Cheryl A Murphy,et al.  Development and application of the adverse outcome pathway framework for understanding and predicting chronic toxicity: I. Challenges and research needs in ecotoxicology. , 2015, Chemosphere.

[56]  P. Sengupta The Laboratory Rat: Relating Its Age With Human's , 2013, International journal of preventive medicine.

[57]  T. Knudsen,et al.  A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing. , 2012, ALTEX.

[58]  D. Creasy,et al.  Proliferative and Nonproliferative Lesions of the Rat and Mouse Male Reproductive System , 2012, Toxicologic pathology.

[59]  Y. Refaeli,et al.  Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. , 2009, Blood.

[60]  Aldert Piersma,et al.  Scientific principles for the identification of endocrine-disrupting chemicals: a consensus statement , 2016, Archives of Toxicology.

[61]  M E Meek,et al.  New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis , 2013, Journal of applied toxicology : JAT.

[62]  A. Jacobs,et al.  History of Chronic Toxicity and Animal Carcinogenicity Studies for Pharmaceuticals , 2013, Veterinary pathology.